Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Eur J Cancer Care (Engl) ; 27(2): e12799, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29265535

RESUMO

Hepatitis B virus (HBV) reactivation is a remarkable risk during the chemotherapy for solid tumour patients. Nucleos(t)ide analogues (NAs) are recommended as prophylaxis for the reactivation of HBV infection in some cancer patients prior to systemic chemotherapy. Therefore, we performed a meta-analysis aiming to determine the efficacy of prophylactic lamivudine on prevention of HBV reactivation and its related negative outcomes among solid tumour patients with chronic HBV infection receiving systemic chemotherapy. The primary outcome was HBV reactivation, and the secondary outcomes were HBV-related hepatitis, chemotherapy disruption, mortality and tyrosine-methio-nine-aspartate-aspartate (YMDD) mutations. Twelve original researches involving 1,101 patients were analysed in this study. The relative risk of HBV reactivation in patients with lamivudine prophylaxis was significantly lower than that without prophylaxis (RR = 0.17, 95% CL: 0.10-0.29, p < .00001). Lamivudine prophylaxis reduced the relative risk of hepatitis (p < .00001), chemotherapy disruptions (p = .01) and mortality (p = .08) due to HBV reactivation. Lamivudine prophylaxis is effective in reducing HBV reactivation and its related negative outcomes, such as hepatitis and chemotherapy disruption and mortality among chemotherapeutic solid tumour patients with chronic HBV infection. Future studies should lay more emphasis on the early HBV screening, mode of treatment and duration of NAs prophylaxis among solid tumour patients receiving chemotherapy.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Antivirais/uso terapêutico , Hepatite B/prevenção & controle , Lamivudina/uso terapêutico , Neoplasias/tratamento farmacológico , Ativação Viral/efeitos dos fármacos , Humanos , Estudos Retrospectivos
4.
Zhonghua Xin Xue Guan Bing Za Zhi ; 44(9): 782-785, 2016 Sep 24.
Artigo em Chinês | MEDLINE | ID: mdl-27667277

RESUMO

Objective: To observe the clinical feature of familiar hereditary protein S deficiency(HPSD), and to explore the related gene mutations. Methods: A total of seven family members were enrolled in this study and examined during the June to September 2015. Medical histories of the families were analyzed to detect HPSD according to the diagnostic criteria. PROS1 genes of the proband and her family were analyzed. DNA was extracted from peripheral blood. The 15 exons and their intron-exon boundaries of PROS1 were amplified with PCR, and the PCR products were sequenced and analyzed to identify potential mutations. Medical histories from the family members died prior this study were also obtained. Results: Four out of 7 family members of 2 generations were diagnosed as HPSD. The proband suffered from pulmonary embolism, her elder brother suffered from cerebral infarction and her niece suffered from deep vein thrombosis. A missense mutation at the 1063 bp of cDNA(c.1063C>T)was detected in the exon 10 of PROS1, which resulted in arginine 355 to cysteine replacement in the first ball domain of laminin of the protein S(p.R355C). Conclusion: HPSD is an autosomal dominant genetic disease, patients often suffer from recurring vein thrombosis and pulmonary embolism. A missense mutation(c.1063C>T, p. R355C)of PROS1 was discovered in this Chinese family with HPSD, thus, this mutation might be the genetic basis responsible for these family members with HPSD .


Assuntos
Deficiência de Proteína S , Povo Asiático , Éxons , Feminino , Humanos , Masculino , Mutação , Linhagem , Inquéritos e Questionários
7.
Emerg Infect Dis ; 4(2): 311-6, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9621205

RESUMO

Well-documented cases of simultaneous human infection with more than one tick-borne pathogen are rare. To our knowledge only two dual infections have been reported: simultaneous human infection with the agent of human granulocytic ehrlichiosis and Borrelia burgdorferi and simultaneous human infection with B. burgdorferi and Babesia microti (1-2). Rocky Mountain spotted fever has long been known to be endemic in North Carolina; cases of human ehrlichial infection were recognized there soon after Ehrlichia chaffeensis was recognized as an important cause of tick-borne disease in the southeastern United States. Because both Rocky Mountain spotted fever and ehrlichiosis are prevalent in North Carolina, occasional cases of simultaneous human infection by rickettsial and ehrlichial agents would not be surprising; however, no such cases seem to have been reported.


Assuntos
Ehrlichia chaffeensis , Ehrlichiose/complicações , Febre Maculosa das Montanhas Rochosas/complicações , Adulto , Ehrlichia chaffeensis/genética , Ehrlichia chaffeensis/isolamento & purificação , Ehrlichiose/diagnóstico , Imunofluorescência , Genes Bacterianos , Humanos , Masculino , Reação em Cadeia da Polimerase , Rickettsia rickettsii/isolamento & purificação , Febre Maculosa das Montanhas Rochosas/sangue , Febre Maculosa das Montanhas Rochosas/diagnóstico , Análise de Sequência de DNA , Pele/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA